Pharmaceutical News

RSS

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Catalyst Pharmaceutical Partners, Inc. today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management.

9 Jul 2010

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia.

9 Jul 2010

Semuloparin reduces incidence of VTE in orthopedic surgery patients, study finds

An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.

9 Jul 2010

Derma Sciences submits 510(k) application to FDA for MEDIHONEY Gel Wound & Burn Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces the achievement of regulatory and commercial milestones.

9 Jul 2010

Allergan receives UK MHRA authorisation of BOTOX for prophylaxis of headache in chronic migraine

Allergan is pleased to announce that BOTOX® (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). This is the first licence worldwide of BOTOX® for this indication, and is also the first prophylactic (preventative) treatment to receive a specific licence for patients with chronic migraine.

9 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Hormonal contraceptives are less effective for birth control in overweight or obese women: Study

As obesity continues to be a worldwide health risk, one of its "side effects" could include less effective birth control for overweight and obese women who use hormonal contraceptives.

9 Jul 2010

Accudial's weight-based rotating labels prevent underdosing and overdosing in children's OTC medications

There is plenty to worry about when it comes to the job of parenting. However, wondering if a child is receiving the correct amount of over-the-counter (OTC) medication can now be a concern of the past, thanks to Children's AccuDial(R), a patented new line of children's medication available across Canada, with a dosing system based on body weight, not age.

9 Jul 2010

Que She herbal weight loss supplement contains harmful ingredients, FDA warns

The U.S. Food and Drug Administration today warned that Que She, marketed as an herbal weight loss supplement, contains active pharmaceutical ingredients not listed on the product label that could harm consumers, especially those with cardiovascular conditions.

9 Jul 2010

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

FDA approves Roxane's Naratriptan Tablets ANDA

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Naratriptan Tablets USP, 1mg and 2.5mg by the U.S. Food and Drug Administration. The product is available in bottles of 9 for immediate shipment to wholesalers and pharmacies nationwide.

9 Jul 2010

Roxane announces FDA approval for Anastrozole Tablets ANDA

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the U.S. Food and Drug Administration. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies nationwide.

9 Jul 2010

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

The U.S. Food and Drug Administration today warned that the unapproved use of the malaria drug Qualaquin (quinine sulfate) to treat night time leg cramps has resulted in serious side effects and prompted the manufacturer to develop a risk management plan aimed at educating health care professionals and patients about the potential risks.

9 Jul 2010

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, and Intellikine, Inc., a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, today announced an agreement under which Infinity obtained global development and commercialization rights to Intellikine's portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase.

8 Jul 2010

pSivida submits MAA for Iluvien to UK MHRA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.

8 Jul 2010

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.

8 Jul 2010

Shire files patent infringement lawsuit against Zydus

Shire plc, the global specialty biopharmaceutical company, announces that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the U.S. District Court for the District of Delaware against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals, Inc. for the infringement of U.S. Patent No. 6,773,720.

8 Jul 2010

Standard Process launches new ProSynbiotic product

By our first birthday, we've acquired over 400 bacterial passengers in our gastrointestinal tract. Our gut microbes, or "bugs," work to keep our complex and diverse gut ecosystem in balance. Unfortunately, the trials of daily life-stressful events, aging, diet, or immune challenges-can be hard on these bugs. Standard Process Inc. introduces a new product, ProSynbiotic, to help our body maintain a healthy, balanced gut ecosystem.

8 Jul 2010

Article related to MN-166 mechanism of action included in PNAS USA

MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported that the June 22, 2010 issue of Proceedings of the National Academy of Sciences USA included an article related to the mechanism of action of MN-166 (ibudilast), as an emerging therapeutic for neurological disorders.

8 Jul 2010

Local anesthetics have potential therapeutic effects on IBD: Research article

Inflammatory bowel disease is a disease of the gastrointestinal tract, mainly the intestines that may occur in the people who have genetic potential with a contribution of environmental factors. There has been no definitive medical treatment and drugs usually help the symptoms just to relieve.

8 Jul 2010

Pharmaceutical News

EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Semuloparin reduces incidence of VTE in orthopedic surgery patients, study finds

Derma Sciences submits 510(k) application to FDA for MEDIHONEY Gel Wound & Burn Dressing

Allergan receives UK MHRA authorisation of BOTOX for prophylaxis of headache in chronic migraine

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Hormonal contraceptives are less effective for birth control in overweight or obese women: Study

Accudial's weight-based rotating labels prevent underdosing and overdosing in children's OTC medications

Que She herbal weight loss supplement contains harmful ingredients, FDA warns

IRIC scientists identify vitamin B3 as potential antifungal treatment

FDA approves Roxane's Naratriptan Tablets ANDA

Roxane announces FDA approval for Anastrozole Tablets ANDA

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

pSivida submits MAA for Iluvien to UK MHRA

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Shire files patent infringement lawsuit against Zydus

Standard Process launches new ProSynbiotic product

Article related to MN-166 mechanism of action included in PNAS USA

Local anesthetics have potential therapeutic effects on IBD: Research article

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News